
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings is seeing a strong recovery in their financials, with total revenues growing by 105% quarter-over-quarter to reach $4.22M in 3Q25. This improvement is driven by a rebound in enterprise sales, as previous order delays have been resolved. Additionally, gross margins also improved significantly from the previous quarter.
Bears say
Ekso Bionics Holdings is undergoing major restructuring through the sale of their legacy MedTech business and exploration of strategic transactions. This could lead to a significant decrease in revenue and uncertainty for the company's future performance. Without a clear timeline or insight into these potential transactions, it is difficult to forecast the impact on the company's financials, making it a risky investment option.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares